NRG-GI005

Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA)

Schema & Eligibility NRG-GI005

Available at:

CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Delbert Day Cancer Institute at PCRMC, Rolla, MO
Freeman Health System, Joplin, MO
Good Samaritan Regional Health Center, Mt. Vernon, IL
Mercy Hospital, St. Louis, MO
Mercy South, St. Louis, MO
Mercy Hospital, Oklahoma City, OK
Mercy Hospital, Joplin, MO
Mercy Hospital, Ft. Smith, AR
Mercy Clinic Cancer & Hematology, Rolla, MO
Mosaic Life Care, St. Joseph, MO

Ask your physician about participating in this clinical trial or call us.